Genmab A/S
NASDAQ:GMAB · NASDAQ Global Select
-$0.12 today
Vol 1.81M · Avg 1.85M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:GMAB · Revenue to Net Income
Key Ratios
Analysis
$3.9B of revenue converted into $821.0M of net income for the selected period. Gross margin is 93.3% and net margin is 21.1%, showing how much revenue survives after costs and taxes. EPS is $1.32, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B -82.7% | $21.5B +30.7% | $16.5B +13.6% | $14.5B +72.3% | $8.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $309.2M -68.6% | $985.0M +335.8% | $226.0M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.4B -83.4% | $20.5B +26.4% | $16.2B +12.0% | $14.5B +72.3% | $8.4B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 91.7% -3.7pp | 95.4% -3.2pp | 98.6% -1.4pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.6B -84.0% | $9.7B +27.8% | $7.6B +37.2% | $5.6B +33.0% | $4.2B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $602.5M -84.1% | $3.8B +15.0% | $3.3B +23.2% | $2.7B +108.6% | $1.3B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.2B -84.4% | $13.8B +26.6% | $10.9B +32.6% | $8.2B +50.8% | $5.5B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $71.1M -82.8% | $413.0M +72.1% | $240.0M -33.7% | $362.0M +44.8% | $250.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.3B -86.2% | $9.7B +63.1% | $5.9B -19.0% | $7.3B +75.7% | $4.2B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 35.9% -9.1pp | 45.0% +8.9pp | 36.1% -14.5pp | 50.6% +1.0pp | 49.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.3B -81.3% | $6.7B +26.0% | $5.3B -15.1% | $6.3B +112.2% | $3.0B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 33.6% +2.5pp | 31.1% -1.2pp | 32.3% -10.9pp | 43.2% +8.1pp | 35.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $138.1M -86.1% | $995.0M +6.0% | $939.0M +189.8% | $324.0M +64.5% | $197.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $61.0M -49.1% | $120.0M +344.4% | $27.0M +28.6% | $21.0M +61.5% | $13.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$46.0M -101.9% | $2.5B +678.8% | $316.0M -53.4% | $678.0M -29.7% | $965.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.2B -86.9% | $9.2B +62.6% | $5.6B -18.8% | $6.9B +77.3% | $3.9B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 32.4% -10.2pp | 42.6% +8.4pp | 34.2% -13.7pp | 47.9% +1.3pp | 46.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $241.2M -81.7% | $1.3B +2.7% | $1.3B -13.9% | $1.5B +55.4% | $961.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $963.8M -87.7% | $7.8B +80.2% | $4.4B -20.2% | $5.5B +84.4% | $3.0B | $4.9B | $4.8B | $4.7B |
| Net Margin | 25.9% -10.6pp | 36.4% +10.0pp | 26.4% -11.2pp | 37.6% +2.5pp | 35.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 -87.2% | $12 +83.9% | $7 -20.9% | $8 +84.5% | $5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 -87.3% | $12 +83.9% | $7 -20.1% | $8 +84.4% | $4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $621.5M -3.8% | $646.3M -1.9% | $659.2M +0.8% | $653.9M -0.0% | $654.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $626.9M -3.0% | $646.3M -1.9% | $659.1M -0.1% | $660.1M -0.1% | $660.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.07B
United Therapeutics Corporation
NASDAQ:UTHR
$23.41B
Royalty Pharma plc
NASDAQ:RPRX
$23.10B
Roivant Sciences Ltd.
NASDAQ:ROIV
$22.44B
Quest Diagnostics Incorporated
NYSE:DGX
$21.89B
Incyte Corporation
NASDAQ:INCY
$19.78B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$16.86B
Tenet Healthcare Corporation
NYSE:THC
$15.38B
Exelixis, Inc.
NASDAQ:EXEL
$13.18B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.91B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GMAB generate?
Genmab A/S (GMAB) reported $3.72B of revenue in fiscal 2025.
Is GMAB profitable?
Genmab A/S (GMAB) reported $963.76M of net income, with a net margin of 25.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.